Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma-Reference-Cited by-同舟云学术

Pharmacologic screen identifies active combinations with BET inhibitors and LRRK2 as a novel putative target in lymphoma

Published:2022-07-27 Issue:3 Volume:3 Page:764-774
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Spriano Filippo¹,Sartori Giulio¹,Tarantelli Chiara¹,Barreca Marilia¹²,Golino Gaetanina¹,Rinaldi Andrea¹,Napoli Sara¹,Mascia Michele¹,Scalise Lorenzo¹,Arribas Alberto J.¹³,Cascione Luciano¹³,Zucca Emanuele¹⁴,Stathis Anastasios⁴⁵,Gaudio Eugenio¹,Bertoni Francesco¹⁴

Affiliation:

1. Institute of Oncology Research Faculty of Biomedical Sciences Università della Svizzera Italiana Bellinzona Switzerland

2. Department of Biological Chemical and Pharmaceutical Sciences and Technologies (STEBICEF) University of Palermo Palermo Italy

3. SIB Swiss Institute of Bioinformatics Lausanne Switzerland

4. Department of Oncology Oncology Institute of Southern Switzerland Ente Ospedaliero Cantonale Bellinzona Switzerland

5. Faculty of Biomedical Sciences Università della Svizzera Italiana Lugano Switzerland

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.535

Reference54 articles.

1. Targeting BET bromodomain proteins in cancer: The example of lymphomas

2. Make your best BET: The emerging role of BET inhibitor treatment in malignant tumors

3. Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

4. Blockade of oncogenic I B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors

5. The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of a novel humanized heavy chain antibody targeting endogenous retroviruses with anti-lymphoma activity;2024-01-18